Marta Ferrer Puga
Director
Allergology and Immunology Department
Clinica Universidad de Navarra
Spain
Biography
Head of the Allergology Department
Research Interest
Throughout her professional career, she has carried out research on chronic hives. Currently, she is focussing her work on the study of the activation and role of basophiles and the response of immunomodulatories. Additionally, in the last few years, she has done research on the design of immunotherapy through nanotechnology. She is the co-author of two international patents on immunotherapy with nanotechnology. At the moment, she is leading two national multi-centre clinical trials. The first is about the efficiency and safety of Omalizumab (Xolair®) for the treatment of chronic hives (ClinicalTrials.gov Identifier: NCT01713725). And, the second is studying the efficiency and safety of Omalizumab (Xolair®) for the treatment of Cholinergic Hives (Clinicaltrials.gov Identifier: NCT02012387).
